1. Cell Biology
  2. Immunology and Inflammation

HIF-1α induces glycolytic reprograming in tissue-resident alveolar macrophages to promote cell survival during acute lung injury

  1. Parker S Woods
  2. Lucas M Kimmig
  3. Kaitlyn A Sun
  4. Angelo Y Meliton
  5. Obada R Shamaa
  6. Yufeng Tian
  7. Rengül Cetin-Atalay
  8. Willard W Sharp
  9. Robert B Hamanaka
  10. Gökhan M Mutlu  Is a corresponding author
  1. University of Chicago, United States
https://doi.org/10.7554/eLife.77457
Share this article
Cite this article
  1. Parker S Woods
  2. Lucas M Kimmig
  3. Kaitlyn A Sun
  4. Angelo Y Meliton
  5. Obada R Shamaa
  6. Yufeng Tian
  7. Rengül Cetin-Atalay
  8. Willard W Sharp
  9. Robert B Hamanaka
  10. Gökhan M Mutlu
(2022)
HIF-1α induces glycolytic reprograming in tissue-resident alveolar macrophages to promote cell survival during acute lung injury
eLife 11:e77457.
https://doi.org/10.7554/eLife.77457
  2. Download BibTeX
  3. Download .RIS

Abstract

Cellular metabolism is a critical regulator of macrophage effector function. Tissue-resident alveolar macrophages (TR-AMs) inhabit a unique niche marked by high oxygen and low glucose. We have recently shown that in contrast to bone marrow-derived macrophages (BMDMs), TR-AMs do not utilize glycolysis and instead predominantly rely on mitochondrial function for their effector response. It is not known how changes in local oxygen concentration that occur during conditions such as acute respiratory distress syndrome (ARDS) might affect TR-AM metabolism and function; however, ARDS is associated with progressive loss of TR-AMs, which correlates with the severity of disease and mortality. Here, we demonstrate that hypoxia robustly stabilizes HIF-1α in TR-AMs to promote a glycolytic phenotype. Hypoxia altered TR-AM metabolite signatures, cytokine production, and decreased their sensitivity to the inhibition of mitochondrial function. By contrast, hypoxia had minimal effects on BMDM metabolism. The effects of hypoxia on TR-AMs were mimicked by FG-4592, a HIF-1α stabilizer. Treatment with FG-4592 decreased TR-AM death and attenuated acute lung injury in mice. These findings reveal the importance of microenvironment in determining macrophage metabolic phenotype, and highlight the therapeutic potential in targeting cellular metabolism to improve outcomes in diseases characterized by acute inflammation.

Data availability

Source Data files have been provided for Figures 2C, and 5B, C.

Article and author information

Author details

  1. Parker S Woods

    Department of Medicine, University of Chicago, Chicago, United States
    Competing interests
    Parker S Woods, has a pending patent on targeting tissue-resident alveolar macrophage metabolism to prevent their death during ARDS. (ARCD.P0740US.P1/1001176943).

  2. Lucas M Kimmig

    Department of Medicine, University of Chicago, Chicago, United States
    Competing interests
    No competing interests declared.

  3. Kaitlyn A Sun

    Department of Medicine, University of Chicago, Chicago, United States
    Competing interests
    No competing interests declared.

  4. Angelo Y Meliton

    Department of Medicine, University of Chicago, Chicago, United States
    Competing interests
    No competing interests declared.

  5. Obada R Shamaa

    Department of Medicine, University of Chicago, Chicago, United States
    Competing interests
    No competing interests declared.

  6. Yufeng Tian

    Department of Medicine, University of Chicago, Chicago, United States
    Competing interests
    No competing interests declared.

  7. Rengül Cetin-Atalay

    Department of Medicine, University of Chicago, Chicago, United States
    Competing interests
    No competing interests declared.

  8. Willard W Sharp

    Department of Medicine, University of Chicago, Chicago, United States
    Competing interests
    No competing interests declared.

  9. Robert B Hamanaka

    Department of Medicine, University of Chicago, Chicago, United States
    Competing interests
    Robert B Hamanaka, has a pending patent on targeting tissue-resident alveolar macrophage metabolism to prevent their death during ARDS. (ARCD.P0740US.P1/1001176943).
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8909-356X

  10. Gökhan M Mutlu

    Department of Medicine, University of Chicago, Chicago, United States
    For correspondence
    gmutlu@medicine.bsd.uchicago.edu
    Competing interests
    Gökhan M Mutlu, has a pending patent on targeting tissue-resident alveolar macrophage metabolism to prevent their death during ARDS. (ARCD.P0740US.P1/1001176943).
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2056-612X

Funding

U.S. Department of Defense (W81XWH-16-1-0711)

  • Gökhan M Mutlu

National Institute of Environmental Health Sciences (R01ES010524)

  • Gökhan M Mutlu

National Heart, Lung, and Blood Institute (R01HL151680)

  • Robert B Hamanaka

National Institute of Environmental Health Sciences (U01ES026718)

  • Gökhan M Mutlu

National Heart, Lung, and Blood Institute (P01HL144454)

  • Gökhan M Mutlu

National Heart, Lung, and Blood Institute (T32HL007605)

  • Parker S Woods
  • Lucas M Kimmig
  • Obada R Shamaa
  • Gökhan M Mutlu

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All animal experiments and procedures were performed according to the protocols (ACUP7236 and ACUP72484) approved by the Institutional Animal Care and Use Committee at the University of Chicago.

Copyright

© 2022, Woods et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,885
    views
  • 628
    downloads
  • 25
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Parker S Woods
  2. Lucas M Kimmig
  3. Kaitlyn A Sun
  4. Angelo Y Meliton
  5. Obada R Shamaa
  6. Yufeng Tian
  7. Rengül Cetin-Atalay
  8. Willard W Sharp
  9. Robert B Hamanaka
  10. Gökhan M Mutlu
(2022)
HIF-1α induces glycolytic reprograming in tissue-resident alveolar macrophages to promote cell survival during acute lung injury
eLife 11:e77457.
https://doi.org/10.7554/eLife.77457

Share this article

https://doi.org/10.7554/eLife.77457

Categories and tags

Research organism

Further reading

    1. Cell Biology

    Small-molecule activation of TFEB alleviates Niemann–Pick disease type C via promoting lysosomal exocytosis and biogenesis

    Kaili Du, Hongyu Chen ... Dan Li
    Research Article

    Niemann–Pick disease type C (NPC) is a devastating lysosomal storage disease characterized by abnormal cholesterol accumulation in lysosomes. Currently, there is no treatment for NPC. Transcription factor EB (TFEB), a member of the microphthalmia transcription factors (MiTF), has emerged as a master regulator of lysosomal function and promoted the clearance of substrates stored in cells. However, it is not known whether TFEB plays a role in cholesterol clearance in NPC disease. Here, we show that transgenic overexpression of TFEB, but not TFE3 (another member of MiTF family) facilitates cholesterol clearance in various NPC1 cell models. Pharmacological activation of TFEB by sulforaphane (SFN), a previously identified natural small-molecule TFEB agonist by us, can dramatically ameliorate cholesterol accumulation in human and mouse NPC1 cell models. In NPC1 cells, SFN induces TFEB nuclear translocation via a ROS-Ca2+-calcineurin-dependent but MTOR-independent pathway and upregulates the expression of TFEB-downstream genes, promoting lysosomal exocytosis and biogenesis. While genetic inhibition of TFEB abolishes the cholesterol clearance and exocytosis effect by SFN. In the NPC1 mouse model, SFN dephosphorylates/activates TFEB in the brain and exhibits potent efficacy of rescuing the loss of Purkinje cells and body weight. Hence, pharmacological upregulating lysosome machinery via targeting TFEB represents a promising approach to treat NPC and related lysosomal storage diseases, and provides the possibility of TFEB agonists, that is, SFN as potential NPC therapeutic candidates.

    1. Cell Biology

    Stratification of enterochromaffin cells by single-cell expression analysis

    Yan Song, Linda J Fothergill ... Gene W Yeo
    Research Article

    Dynamic interactions between gut mucosal cells and the external environment are essential to maintain gut homeostasis. Enterochromaffin (EC) cells transduce both chemical and mechanical signals and produce 5-hydroxytryptamine to mediate disparate physiological responses. However, the molecular and cellular basis for functional diversity of ECs remains to be adequately defined. Here, we integrated single-cell transcriptomics with spatial image analysis to identify 14 EC clusters that are topographically organized along the gut. Subtypes predicted to be sensitive to the chemical environment and mechanical forces were identified that express distinct transcription factors and hormones. A Piezo2+ population in the distal colon was endowed with a distinctive neuronal signature. Using a combination of genetic, chemogenetic, and pharmacological approaches, we demonstrated Piezo2+ ECs are required for normal colon motility. Our study constructs a molecular map for ECs and offers a framework for deconvoluting EC cells with pleiotropic functions.

    1. Cell Biology
    2. Developmental Biology

    Lens Development: Bringing signaling complexity into focus

    Sarah Y Coomson, Salil A Lachke
    Insight

    A study in mice reveals key interactions between proteins involved in fibroblast growth factor signaling and how they contribute to distinct stages of eye lens development.